T2007 Seattle, Washington

Similar documents
A Simple and Accurate Method for the Rapid Quantitation of Drugs of Abuse in Urine Using Liquid Chromatography

Validation of a Benzodiazepine and Z-Drug Method Using an Agilent 6430 LC/MS/MS

E XCEL LENCE JUST GOT BETTER UCT FORENSICS CLEAN SCREEN XCEL SPE COLUMNS

A Comprehensive Screening of Illicit and Pain Management Drugs from Whole Blood Using SPE and LC/MS/MS

Application Note LCMS-108 Quantitation of benzodiazepines and Z-drugs in serum with the EVOQ TM LC triple quadrupole mass spectrometer

Amphetamines, Phentermine, and Designer Stimulant Quantitation Using an Agilent 6430 LC/MS/MS

LCMS-8050 Drugs of Abuse: 113 Analytes with Polarity Switching

Automated Targeted screening of Benzodiazepines in urine using LDTD-MS/MS at 400 samples per hour rate

Ultrafast Analysis of Benzodiazepines in Urine by the Agilent RapidFire High-Throughput Triple Quadrupole Mass Spectrometry System

Determination of 78 Banned or Controlled Racing Industry Drugs in Horse Urine Using SPE and LC-MS/MS

Evaluation of an LC-MS/MS Research Method for the Analysis of 33 Benzodiazepines and their Metabolites

Analysis of anti-epileptic drugs in human serum using an Agilent Ultivo LC/TQ

Forensic Toxicology Scope of Testing and Detection Limits

Determination of Benzodiazepines in Urine by CE-MS/MS

A Rapid Method for Detection of Drugs of Abuse in Blood Samples Using the Thermal Separation Probe and the 5975T LTM GC/MS

1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia

A Robustness Study for the Agilent 6470 LC-MS/MS Mass Spectrometer

4.5 Minute Analysis of Benzodiazepines in Urine and Whole Blood Using LC/MS/MS and an Ultra Biphenyl Column

Quantitative Analysis of Drugs of Abuse in Urine using UHPLC Coupled to Accurate Mass AxION 2 TOF Mass Spectrometer

Validation Report for the Neogen Fentanyl Kit for ELISA Screening of Whole Blood and Urine Specimens

Analyze Barbiturates in Urine with Agilent 6430 LC/MS/MS and Poroshell 120 EC-C18

DETERMINATION OF CANNABINOIDS, THC AND THC-COOH, IN ORAL FLUID USING AN AGILENT 6490 TRIPLE QUADRUPOLE LC/MS

Supporting Information

High-Throughput Quantitative LC-MS/MS Analysis of 6 Opiates and 14 Benzodiazepines in Urine

Offline and online sample extraction for the quantification of benzodiazepines in human plasma or serum for clinical research

Determination of β2-agonists in Pork Using Agilent SampliQ SCX Solid-Phase Extraction Cartridges and Liquid Chromatography-Tandem Mass Spectrometry

Quantitative Determination of Drugs of Abuse in Human Plasma and Serum by LC/MS/MS Using Agilent Captiva EMR Lipid Cleanup

Fully Automated Online Sample Preparation and LC-MS/MS Analysis of Drugs of Abuse in Oral Fluids

Application Note. Author. Abstract. Introduction. Food Safety

Rapid Hydrolysis of Benzodiazepines in Urine. Alicia Zook 1 and Crystal Xander B.S. 2. Cedar Crest College, Allentown, PA 1

A FORENSIC TOXICOLOGY METHOD FOR THE DETERMINATION OF DESOMORPHINE, HEROIN, METHADONE, BUPRENORPHINE AND METABOLITES IN URINE USING LC/MS QQQ

Agilent Clinical LC/MS: Review of Established LC-MS QQQ Clinical Research Applications. dr. Jan Srbek, HPST. Page 1

Cannabinoid Quantitation Using an Agilent 6430 LC/MS/MS

The Development of LC/MS Methods for Determination of Polar Drugs of Abuse in Biological Samples

Determination of Bath Salts (Pyrovalerone Analogs) in Biological Samples

Overview. Introduction. Experimental. Cliquid Software for Routine LC/MS/MS Analysis

Evaluation of the Impact of Expanding ELISA Screening in DUID Investigations. Aileen Lu*, Karen S. Scott, Aya Chan-Hosokawa, and Barry K.

Quantitative Analysis of Amphetamine-Type Drugs by Extractive Benzoylation and LC/MS/MS. Application. Introduction. Authors. Abstract.

Rapid LC/TOF MS for Analytical Screening of Drugs in the Clinical Research Lab

A Novel Platform of On-line Sample Pre-treatment and LC/MS/MS Analysis for Screening and Quantitation of Illicit Drugs in Urine

Qualitative and quantitative determination of cannabinoid profiles and potency in CBD hemp oil using LC/UV and Mass Selective Detection

Determination of Amphetamine and Derivatives in Urine

All stocks and calibration levels were prepared in water: methanol (50:50) v/v to cover range of all steroid concentrations (refer Table 1).

Simultaneous Determination of Prescription and Designer Benzodiazepines in Urine and Blood by SPE and LC-MS/MS

One Source Toxicology Laboratory, 1213 Genoa Red Bluff, Pasadena, Texas 77504

Lyndsey Knoy, D-ABFT-FT Forensic Scientist Washington State Toxicology Laboratory.

Quantitative Analysis of Opiates in Urine Using RRHT LC/MS/MS. Application. Authors. Introduction. Abstract. Forensics

Authors. Abstract. Introduction. Environmental

LC-MS/MS Method for the Determination of Tenofovir from Plasma

Drugs of Abuse in Oral Fluids: Automated SPE Extraction and LC/MS/MS Determination using a Robotic Autosampler

Rapid and Sensitive Analysis of a 93-Compound Forensic Panel in Urine using the QTRAP /Triple Quad 4500 LC- MS/MS System

A RAPID AND SENSITIVE ANALYSIS METHOD OF SUDAN RED I, II, III & IV IN TOMATO SAUCE USING ULTRA PERFORMANCE LC MS/MS

Reduced Ion Suppression and Improved LC/MS Sensitivity with Agilent Bond Elut Plexa

application Natural Food Colorants Analysis of Natural Food Colorants by Electrospray and Atmospheric Pressure Chemical Ionization LC/MS

Automated ion trap LC-MS screening for xenobiotics in vitreous humour

SPE-LC-MS/MS Method for the Determination of Nicotine, Cotinine, and Trans-3-hydroxycotinine in Urine

Improving Benzodiazepine Immunoassay Sensitivity by Rapid Glucuronide Hydrolysis Technology

[ APPLICATION NOTE ] APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS KEYWORDS

Applications of High Resolution Mass Spectrometry in Forensic Toxicology. Patrick Kyle, PhD.

Quantification of lovastatin in human plasma by LC/ESI/MS/MS using the Agilent 6410 Triple Quadrupole LC/MS system

Development of a Screening Analysis by LC Time-Of-Flight MS for Drugs of Abuse Application

Extraction of 11-nor-9-carboxy-tetrahydrocannabinol from Hydrolyzed Urine by ISOLUTE. SLE+ Prior to GC/MS Analysis

Cannabinoid Profiling and Quantitation in Hemp Extracts using the Agilent 1290 Infinity II/6230B LC/TOF system

Determination of Gamma-Hydroxy-Butyrate (GHB) in Biological Samples

Comparison of Different Whole Blood Sample Pretreatment Methods for Targeted Analysis of Basic Drugs

Extraction of a Comprehensive Steroid Panel from Human Serum Using ISOLUTE. SLE+ Prior to LC/MS-MS Analysis

Analysis of Testosterone, Androstenedione, and Dehydroepiandrosterone Sulfate in Serum for Clinical Research

Fast and easy separation of 23 drugs of abuse. including high, stable resolution of isobaric opioids from human urine by UHPLC-MS/MS

The Drug Testing Process. Employer or Practice

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years

Possibility of Use a Saliva for Determination Ethanol and Opiates

Authors. Abstract. Forensic Toxicology. Irina Dioumaeva, John M. Hughes Agilent Technologies, Inc.

BENZODIAZEPINE FINDINGS IN BLOOD AND URINE BY GAS CHROMATOGRAPHY AND IMMUNOASSAY

Screening and quantitation of drugs in oral fluids using Q Exactive system

Liquid Liquid Extraction of Gamma Hydroxybutyric Acid (GHB) in Blood and Urine for GC-MS analysis

Quantitative Determination of Drugs of Abuse in Human Whole Blood by LC/MS/MS Using Agilent Captiva EMR Lipid Cleanup

Detection of Cannabinoids in Oral Fluid with the Agilent 7010 GC-MS/MS System

Vitamin D3 and related compounds by ESI and APCI

Analysis of drugs of abuse in biological matrix using Time of Flight technology

Jonathan Rochon, Pier-Luc Plante, Serge Auger, Réal Paquin, Jacques Corbeil, Pierre Picard

Your Results are Our Priority.

PosterREPRINT SIMULTANEOUS QUANTIFICATION OF PSYCHOTHERAPEUTIC DRUGS IN HUMAN PLASMA BY TANDEM MASS SPECTROMETRY

Determination of Opiates and Metabolites in Blood Using Electrospray LC/MS. Application Note

ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS

Rapid and Accurate LC-MS/MS Analysis of Nicotine and Related Compounds in Urine Using Raptor Biphenyl LC Columns and MS-Friendly Mobile Phases

INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE, MARYLAND QUARTERLY REPORT: FOURTH QUARTER, 2008 AND 2008 SUMMARY

September HCMC Toxicology Transition: Additional information and Frequently Asked Questions

Screening of Antihistamine Agents (Diphenhydramine) with Blood and Urine Samples by REMEDi-HS System

Validation of an Automated Method to Remove

Application. Detection of Cannabinoids in Oral Fluid Using Inert Source GC/MS. Introduction. Authors. Abstract. Forensic Toxicology

Application Note. Abstract. Authors. Pharmaceutical

Screening by immunoassay and confirmation & quantitation by GC-MS of buprenorphine and norbuprenorphine in urine, whole blood and serum

Direct Analysis of Urinary Opioids and Metabolites by Mixed-Mode µelution SPE Combined with UPLC/MS/MS for Forensic Toxicology

Urine Drug Testing Methods 3-5

Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population

Identification and Quantification of 22 Benzodiazepines in Postmortem Fluids and Tissues using UPLC/MS/MS

Frequently Asked Questions: Opiate Dependency and Methadone Maintenance Treatment program follow-up

DIRECT EXTRACTION OF BENZODIAZEPINE METABOLITE WITH SUPERCRITICAL FLUID FROM WHOLE BLOOD

Analyze Drugs of Abuse with Agilent J&W Ultimate Plus Tubing in an Inert Flow Path

Application of LC/Electrospray Ion Trap Mass Spectrometry for Identification and Quantification of Pesticides in Complex Matrices

Transcription:

T2007 Seattle, Washington Application of Liquid Chromatography-Mass Spectrometry with Atmospheric Pressure Chemical Ionization as a Screening Method for forty-two Date-Rape Drugs Piotr Adamowicz*, Maria Kala Institute of Forensic Research, ul. Westerplatte 9, 31-033 Krakow, Poland Piotr Adamowicz ul. Westerplatte 9 31-033 Krakow Tel.: +48 12 4228755 Fax.: +48 12 4223850 E-mail: padamowi@ies.krakow.pl * Author to whom correspondence should be addressed Abstract The phenomenon of drug-facilitated crimes (sexual assaults, robbery) is common in many countries. Because of wide variety of substances used as date-rape drugs, their low concentration in blood and the long delay between the alleged crime and clinical examination, analysis of biological fluids collected from victims of rapes for presence of these drugs was rare up to now. The aim of this study was to develop and apply a LC-APCI- MS screening procedure for date-rape drugs in blood. Target analytes were isolated using liquid-liquid extraction. Analyses were carried out using an Agilent LC/MS operating in APCI mode. Detection of all compounds was based on pseudomolecular ions that were monitored in 6 groups up to 19 ions in each group. Accuracy of the method was verified in the Qualitative Screening Analysis Program of the International Proficiency Testing Scheme with clonidine assigned concentration of 50 ng/ml. The procedure can be easily expanded for more substances. The LC-APCI-MS procedure was successfully applied to the analysis of authentic blood samples collected from victims of rapes in routine casework. Keywords: Drug-facilitated sexual assault, Drug screening, LC-APCI-MS INTRODUCTION Because of pharmacological properties, especially inducing amnesia, many drugs have been identified as so-called date-rape drugs for the purpose of drugging unsuspected victims and than raping them. In a typical scenario, the perpetrator surreptitiously adds date-rape drug to the alcoholic or non-alcoholic beverage of an unsuspecting person, who is subsequently sexually assaulted while under the influence of this substance. Many victims do not report the incident until several days after the event or even do not report it at all. They report the incident so late

after the events because they often have problems with remember the course of incident. It causes that victim is not reliable witness for justice. Indicating of presence date-rape drugs in biological fluids is unequivocal evidence of perpetration [6, 8, 10]. Since the beginnings of twenty-first century in Poland increasing number of reports about the drug facilitated sexual assaults have appeared. This increasing tendency is attested to by increasingly frequent domestic press reports on the use of drugs to facilitate sexual assault. This problem is also reflected in the practice of the Institute of Forensic Research in Cracow [1, 2, 3, 5]. In 2000-2007, 128 of this kind of cases were analyzed in the Department of Toxicological Analyses. After 2003 significant increase of these cases was observed, and recently, between 20 and 40 of cases involving date-rape drugs were registered every year. These cases were submitted to the Institute to carry out analyses for presence of narcotic drugs, psychotropic substances and medicine drugs that could have an influence for behaviour of persons. At present, blood is the main material delivered for investigation. Concentrations of many drugs in this material are low. Moreover victims report the incident late [4, 7, 9]. Because of these many analytical laboratory methods do not allow for detection of date-rape drugs. This situation creates a demand for selective and sensitive analytical screening method to prove the presence of the drug in blood collected from the victim. MATERIALS AND METHODS Chemicals All tested drug standards and deuterated analogues were purchased from Cerilliant Corporation (LGC Promochem, Warszawa, Poland) and from Sigma (Sigma-Aldrich Polska, Poznan, Poland). Biological material Drug-free blood (control blood sample) was taken from a local blood bank and was used for the development and validation of the method. Forensic blood samples were from routine casework elaborated at the Institute of Forensic Research in Cracow.

Liquid-Liquid Extraction Clonazepam-D4, estazolam-d5 and MDMA-D5 were added to two blood samples (0.5 ml each) in eppendorf vials (achieving concentration of 500 ng/ml of each internal standard). Than phosphate buffer ph 2.0 (0.3 ml) and diethyl ether (1.0 ml) were added to one sample (for acidic drugs). Carbonate buffer ph 9.0 (0.5 ml) and ethyl acetate were added to the second one (for basic drugs). Samples were shaken for 5 minutes. After centrifugation at 6000xg for 3 min organic layers were successively evaporated to dryness under a stream of nitrogen on heating block at 37 o C in one vial. The dry residue was reconstituted in 200 μl of mobile phase consisted of acetonitile-water (1:1, v/v). APCI-LC-MS Analysis Analysis was carried out using a Agilent Technologies Series 1100 LC-MS instrument with atmospheric pressure chemical ionisation (APCI) interface (Hewlett Packard, Wilmington, USA). The separation was performed with the use of a LiChroCART Purospher STAR RP-18e 125 x 4 mm (Merck, Darmstadt, Germany) thermostated at 25 o C. The mobile phase consisted of water and acetonitrile (AcCN) containing 0.1 % (v/v) formic acid. The flow rate was 1.0 ml/min. All analyses were carried out in gradient mode: 0 min 5% AcCN, 20 min 60% AcCN, 21 min 80% AcCN, 23 min 80% AcCN, 24 min 5%, 30 min 5%. The injection volume of the solution was 20 μl. Settings of MSD: positive ions mode, fragmentor voltage 60 V, vaporizer temperature 325 o C, capillary voltage 4000 V, drying gas flow 4 L/min and temperature 320 o C, nebulizer pressure 30 psi, corona current 4.0 μa.

RESULTS AND DISCUSSION The LC-APCI-MS method for the simultaneous screening, detection and quantification of forty-two compounds was developed. The list of date-rape drugs was prepared on the basis of literature and own casework. This list does not contain GHB, related compounds, and barbiturates for which LC-APCI-MS is not a method of choice. Detection of all compounds was based on pseudomolecular ions that were monitored in 6 groups up to 19 ions in each group. Monitored ions, and retention times of all compounds are presented in Table I. Ions for compounds that had retention times ± 1 minute from end or beginning of group were monitored in both neighbouring groups. The drugs were quantified in the SIM mode. No interfering peaks were observed in the extracts of eight blank blood samples. Twenty potential interfering compounds were individually spiked into low quality in-house control samples. All controls quantified within ± 20% of target values and showed no interferences with analytes or internal standards. The LODs with a S/N 3 were determined in the range of 0.1-20 ng/ml in the SIM mode. The LOQs corresponded to the lowest calibrator concentrations with S/N 10. The assay was linear from subtherapeutic (0.5-1.0 ng/ml, 22 compounds) or low therapeutic concentrations (2-10 ng/ml, 14 compounds) up to 1 μg/ml (42 compounds). Linear regression correlation coefficients of the 9-point calibration curves (n=5) were 0.990. In reconstituted extracts the analytes were stable for a period of more than 24 hours at room temperature or for 3 days at 20 0 C. The procedure can be easily expanded for more substances. Accuracy of the method was verified in the Qualitative Screening Analysis Program of the International Proficiency Testing Scheme. Using described method in tested serum sample clonidine was detected and determined at concentration of 43.0 ng/ml. On the basis of result report was known that tested serum was spiked with clonidine at concentration of 50.0 ng/ml and mean value determined by participating laboratories was 40.4 ng/ml The procedure was also successfully applied to the analysis of authentic blood samples collected from victims of rapes in routine casework. In one case morphine at concentration of 23 ng/ml and diazepam at concentrations of 8 ng/ml were found. CONCLUSIONS Recently, in Poland, an increase number of drug facilitated sexual assaults has been observed. In this context the sensitive LC-APCI-MS method for detection of date-rape drugs in blood was developed. Low limits of detection of the method allows for analysis of samples even after long delay between the alleged crime and collection of biological fluids. The procedure was successfully applied to the analysis of authentic blood samples collected from victims of rapes in routine casework. The procedure can be easily modified for more drugs. The method is quantitative screening and positive results should be confirmed by other method because applied equipment allows for monitoring only one ion for each compound in SIM mode.

References: 1. Adamowicz P., Toxicological Analysis In Cases of Facilitation of Rape by Administration of Pharmacological Compound, in Polish, Problemy Kryminalistyki 2005, 248, 26-30. 2. Adamowicz P., Kała M., Date-Rape Drugs Scene in Poland, Przegląd Lekarski, 2005, 62/6, 572-575. 3. Adamowicz P., Kała M., Drugs and Alcohol as Agents Used for Facilitation of Sexual Assault, Problems of Forensic Sciences 2004, 58, 79 90. 4. Adamowicz P., Kała M., Urinary excretion rates of ketamine and norketamine following therapeutic ketamine administration: method and detection window considerations, Journal of Analytical Toxicology 2005, 28, 376-382. 5. Adamowicz P., Zuba D., Kała M., Ketamine: A new substance on the Polish drug market. Problems of Forensic Sciences, 2003, 56, 26-39. 6. ElSohly M.A., Salamone S.J.: Prevalance of drugs used in cases of alleged sexual assault. Journal of Analytical Toxicology, 1999, 23, 141-146. 7. Kasprzak K., Adamowicz P., Kała M., Determination of Gamma-Hydroxybutyrate (GHB) in Urine by Gas Chromatography-Mass Spectrometry with Positive Chemical Ionization (PCI- GC-MS) Method, Problems of Forensic Sciences 2006, 67, 289-300. 8. LeBeau M.A., Mozayani A., Drug-facilitated sexual assault. A forensic handbook. Academic Press, 2001. 9. Negrusz A., Adamowicz P., Saini B.K., Webster D.E., Juhascik M.P., Moore Ch.M., Schlemmer R.F., Detection of ketamine in urine of nonhuman primates after single dose using microplate enzyme-linked immunosorbent assay (ELISA) and NCI-GC-MS, Journal of Analytical Toxicology 2005, 29, s. 163-168. 10. Negrusz A., Gaensslen R.E.: Toxicological investigations in drug-facilitated sexual assault, Problems of Forensic Sciences, 2000, 41, 7-26.

Table I. Ion groups, monitored ions in SIM mode, and retention times of all analyzed compounds TIME (min) GROUP ION (m/z) RETENTION TIME (min) COMPOUND 0.00 1 286 1.39 Morphine 3.00 2 7.00 3 10.00 4 13.00 5 230 4.62 Clonidine 300 4.67 Codeine 136 4.93 Amphetamine 304 5.28 Scopolamine 180 5.37 MDA 150 5.46 Metamphetamine 166 5.65 PMA 199 5.77 MDMA-d5 (ISTD 1) 194 5.79 MDMA 389 6.22 Zopiclone 235 6.48 Lidocaine 238 6.77 Ketamine 207 7.13 Ibuprofen 304 8.77 Cocaine 244 8.94 PCP 308 9.24 Zolpidem 327 9.60 Clozapine 219 10.19 Meprobamate 337 10.92 Fentanyl 326 10.94 Midazolam 256 11.13 Diphenhydramine 468 11.88 Buprenorphine 280 11.96 Doxepin 376 12.34 Haloperidol 267 12.90 Desipramine 281 13.15 Imipramine 375 13.24 Hydroxyzine 264 13.29 Nortryptyline 278 13.54 Amitryptyline 310 13.64 Fluoxetine 295 13.83 Trimipramine 310 14.09 Methadone

287 14.27 Oxazepam 306 14.23 Sertraline 300 14.32 Estazolam-d5 (ISTD 2) 321 14.78 Lorazepam 16.00 6 320 14.96 Clonazepam-d4 (ISTD 3) 309 14.99 Alprazolam 316 15.02 Clonazepam 315 15.92 9-THC 285 16.05 Promethazine 301 16.07 Temazepam 314 16.20 Flunitrazepam 285 17.28 Diazepam Figure 1. Selected ion chromatograms of the extract of blood spiked with 42 analyzed compounds and 3 internal standards to the concentration of 500 ng/ml (for fentanyl to 25 ng/ml). 1 morphine; 2 clonidine; 3 codeine; 4 amphetamine; 5 scopolamine; 6 MDA; 7 metamphetamine; 8 PMA; 9 MDMA-D5; 10 MDMA; 11 zopiclone; 12 lidocaine; 13 ketamina; 14 ibuprofen; 15 cocaine; 16 PCP; 17 zolpidem; 18 clozapine; 19 meprobamate; 20 midazolam; 21 fentanyl; 22 diphenhydramine; 23 buprenorphine; 24 doxepin; 25 haloperidol; 26 desipramine; 27 imipramine; 28 hydroxyzine; 29 nortryptyline; 30 amitryptyline; 31 fluoxetine; 32 trimipramine; 33 oxazepam; 34 - methadone; 35 estazolam-d5; 36 sertraline; 37 lorazepam; 38 alprazolam; 39 clonazepam-d4; 40 clonazepam; 41 9THC; 42 flunitrazepam; 43 promethazine; 44 temazepam; 45 diazepam. Figure 1.